Osmel Companioni Napoles Email & Phone Number

Miami, Florida, United States

• At Sylvester Comprehensive Cancer Center, I lead a variety of laboratory management initiatives, constantly finding ways to streamline processes and enhance efficiency. My role involves developing fine-tuning protocols.
• Successfully enhanced T cell activation and cytotoxicity through drug application, providing valuable insights into potential immunomodulatory therapies.
• Demonstrated the promising role of nitric oxide as an antitumoral agent, significantly reducing tumor size in prostate cancer models using subcutaneous xenografts.
• Identified endoplasmic reticulum stress as a pivotal pathway in drug-induced apoptosis, advancing the understanding of cell death mechanisms crucial for cancer treatments.

Richmond, Virginia, United States

• At Virginia Commonwealth University, I specialized in optimizing DNA cloning and adenovirus production, ensuring high transgene expression and maximizing therapeutic potential. My work involved close collaboration with.
• Achieved a significant reduction in tumor burden by utilizing recombinant adenoviruses with therapeutic transgenes, making strides in immunotherapy applications.
• Explored and clarified the underlying mechanisms of cytotoxicity and tumor suppression across in vitro and in vivo models.
• Improved experimental success rates by utilizing the Adeasy adenoviral vector system to generate oncolytic viruses.

• At Columbia’s Irving Cancer Center, I had the opportunity to lead and coordinate multiple research projects focused on the influence of inflammation on cancer stem cells. My work leveraged transgenic mouse models and.
• Discovered that GPCR signaling suppresses aberrant cell division, effectively limiting mutation accumulation and reducing the risk of gastric tumorigenesis.
• Illustrated how stem cell exhaustion drives colitis progression and how H2-receptor agonists can improve immune regulation and survival outcomes in gastrointestinal disease models.
• Recognized that p53 mutations enhance Barrett’s esophagus progression by altering immune surveillance, promoting cell expansion, and hindering differentiation, contributing to the understanding of cancer progression.

Barcelona, Catalonia, Spain

• During my PhD studies at University of Barcelona, I led an extensive epidemiological study that focused on genetic predispositions to gastric cancer, employing genetic techniques to analyze biological samples. I.
• Identified a immunohistochemical marker (Schlafen 5) that predicts patients with intestinal metaplasia that progress into gastric cancer.
• Characterized gene expression profiles, identifying key signaling pathways in the transition from intestinal metaplasia to malignancy, opening doors to targeted immunotherapies.
• Mapped genetic polymorphisms linked to increased gastric cancer risk, contributing to personalized medicine by identifying genetic factors in cancer susceptibility.

Cuba

Genetic structure and association of genetic polymorphisms with complex diseases in the Cuban population

Doctor Of Philosophy - Phd, Cancer Biology

Bachelor Of Science - Bs, Biology/Biological Sciences, General